Specifically, TP53, as a tumour suppressor gene, has been associated with tumour progression and prognosis in gliomas and meningiomas, with mutations and reduced expression linked to aggressive tumour behaviour and poor prognosis [28]. This evidence concerns the gene TP53 and meningioma.